Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01 2023 - 4:30PM
Business Wire
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing
novel immunological agents to treat various cancers, today
announced that the Compensation Committee of Agenus’ Board of
Directors granted, as of September 1, 2023 (“Grant Date”),
inducement awards to Robin Taylor, Ph.D. in connection with his
appointment as Chief Commercial Officer. The Compensation Committee
approved the awards pursuant to Agenus' 2015 Inducement Equity Plan
and in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards to Dr. Taylor consist of (i) nonqualified options to
purchase 200,000 shares of Agenus common stock with a 10-year term,
an exercise price equal to the closing price of Agenus' common
stock on the Grant Date, and vesting over four years in equal
annual installments, (ii) 100,000 restricted stock units that vest
over three years in equal annual installments and (iii) 250,000
nonqualified options that vest in four equal annual installments
starting on the second anniversary of Dr. Taylor joining Agenus;
provided that each equity award to Dr. Taylor is subject to him
maintaining a service relationship with the company through the
relevant vest date.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or follow us on LinkedIn
and Twitter @agenus_bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230901306999/en/
Investors 917-362-1370
investor@agenusbio.com
Media 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024